scholarly journals Bleomycin-induced pneumonitis in a young Ghanaian male with Hodgkin’s Lymphoma

2020 ◽  
Vol 54 (4) ◽  
pp. 279-283
Author(s):  
Yvonne A. Dei-Adomakoh ◽  
Jane S. Afriyie-Mensah ◽  
Hafisatu Gbadamosi

We report a case of a young Ghanaian male who developed Bleomycin Induced Pneumonitis (BIP) after being treated for Hodgkin’s Lymphoma. Pulmonary toxicity is the most feared complication of bleomycin therapy despite its effectiveness in achieving cure in patients with Hodgkin’s lymphoma and germ cell tumors. BIP has a significant mortality rate if detected late and a high index of suspicion is required in all patients on bleomycin-based therapies with sudden onset of respiratory symptoms.

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5318-5318
Author(s):  
Prabhsimranjot Singh ◽  
Sudhamshi Toom ◽  
Makardhwaj S Shrivastava ◽  
Jason Shaw ◽  
David A Silver ◽  
...  

Abstract Introduction: Second malignancies, including lymphoma, occur at a higher incidence in men previously treated for germ cell tumors than in the general population (1). Synchronous presentation of seminoma and lymphoma is rare but has important ramifications for the treatment of both malignancies. Without clinical vigilance this situation may be easily missed, leading to inappropriate management of each cancer. We describe a patient found to have synchronous seminoma and Hodgkin Lymphoma and discuss the effects of the dual diagnoses on his evaluation and care. Case presentation: A 59 year old male with no significant medical history presented with progressive swelling and erythema of the right testis. Testicular cancer was suspected and he underwent a radical right inguinal orchiectomy. Pathology revealed a 5.7cm seminoma of the testis with lymphovascular invasion and without spermatic cord involvement (pT2) (Fig. 1). His tumor markers including AFP, LDH, and Beta-HCG were normal (S0). A CT scan of the chest, abdomen and pelvis followed by a PET/CT revealed enlarged, hypermetabolic mediastinal, hilar and periportal lymphadenopathy interpreted by the radiologist as concerning for metastatic disease. Given the atypical distribution for lymphadenopathy from testicular seminoma, an excisional biopsy of a left hilar node was performed and revealed Classical Hodgkin Lymphoma with IHC positive for CD15, CD30 and PAX-5 (Fig 2). He denied any B-symptoms and his bone marrow was uninvolved by lymphoma (stage IIIA). Adjuvant therapy for his germ cell tumor, otherwise an important consideration, was deferred and he began chemotherapy with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) for 6 cycles. Interim PET/CT after 2 cycles of ABVD showed a complete response. He has completed 6 cycles of ABVD and chose observation as opposed to single dose of adjuvant carboplatin for his seminoma and is currently under surveillance for both malignancies. Discussion: The unusual coexistence of Hodgkin Lymphoma and seminoma has rarely been documented in medical literature, with three other cases previously reported (2, 3). In each case a biopsy of lymphadenopathy, primarily outside the retroperitoneum, yielded a diagnosis of lymphoma. Both Hodgkin Lymphoma and germ cell tumors commonly involve lymph nodes and present in young men. Lymphadenopathy may understandably be assumed to represent metastatic disease in a young man with known testicular cancer. Clinical vigilance is necessary to question the nature of atypical sites of lymphadenopathy in such a patient, and to pursue the possibility of an alternate diagnosis with a lymph node biopsy. A missed diagnosis of lymphoma in such a patient would also mean harmful over-staging of the germ cell tumor. While these two cancers represent two of the most curable malignancies, their treatment is different and would be grossly wrong if each cancer is not correctly diagnosed and staged. Conclusion: Our report highlights the importance of clinical suspicion of a lymphoma in patients with another cancer and lymphadenopathy not typical of metastatic disease for that tumor type. In such situations a lymph node biopsy is crucial in order to proceed with the correct therapy of each malignancy. While the simultaneous presentation of Hodgkin Lymphoma and seminoma is rare, cases like ours highlight the importance of questioning metastatic disease when lymphoma seems to be a possibility. References 1. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39 2. Dexeus FH, Kilbourn R, Chong C, et al: Association of germ cell tumors and Hodgkins disease. Urology 37:129-134, 1991 3. Gerl, A., Clemm, C., Salat, C., Mittermüller, J., Bomfleur, W. and Wilmanns, W. Testicular cancer and Hodgkin disease in the same patient. (1993) Cancer, 71: 2838-2840. Figure 1 Testicular mass- Seminoma Figure 1. Testicular mass- Seminoma Figure 2 Lymph node biopsy- Classic Hodgkin's lymphoma Figure 2. Lymph node biopsy- Classic Hodgkin's lymphoma Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 26 (8) ◽  
pp. 813-819 ◽  
Author(s):  
Yuki Maruyama ◽  
Takuya Sadahira ◽  
Motoo Araki ◽  
Yosuke Mitsui ◽  
Koichiro Wada ◽  
...  

2018 ◽  
Vol 35 (6) ◽  
Author(s):  
Yuki Maruyama ◽  
Takuya Sadahira ◽  
Yosuke Mitsui ◽  
Motoo Araki ◽  
Koichiro Wada ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5450-5450
Author(s):  
Mubarak M Al-Mansour ◽  
Wafa A Al-jizani ◽  
Turki Al-fayea ◽  
Shafi Ruaa ◽  
Ghieth A Kazkaz ◽  
...  

Abstract Background: Bleomycin pulmonary toxicity (BPT) has been well described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens. As the effects of genetic susceptibility or race on the development of BPT are largely unknown, we intended to examine BPT incidence, risk factors, and its effects on survival in a series of newly diagnosed Saudi Arabian adult HL patients receiving first-line bleomycin-containing chemotherapy. Methods: We carried out a retrospective review of the relevant records of 164 consecutive eligible adult HL patients treated at two centers. Results: BPT was observed in 24 of 164 patients (15%) at a median duration of 4.3 months (range, 1 to 58 months). Older age and history of concomitant lung disease were significantly associated with approximately three- (odds ratio [OR] = 3.38; 95% confidence interval [CI], 1.25-9.13; P = 0.02) and seven-fold (OR = 7.19; 95% CI, 2.64-19.54; P <0.0001) increase in BPT risk, respectively. While more patients in non-BPT group achieved CR as compared with BPT patients (93% vs. 79%; P = 0.048), the actuarial 5-year progression-free (82% vs. 63%; P = 0.29) and overall survival (OS) (94% vs. 76%; P = 0.059) for BPT and non-BPT groups, respectively were not significantly different. Nevertheless, in a multivariate analysis, the earlier incidence time of BPT considered as a time-dependent covariate was the only factor that independently influenced OS (hazard ratio = 0.99; 95% CI, 0.99-1.00; P = 0.002). Conclusion: In Saudi Arabian adult HL patients, the risk of BPT and its effect on survival outcome were comparable to that reported from developed countries. Earlier incidence time of BPT aversely influenced OS. Future studies should consider testing the efficacy and safety of non-bleomycin-containing regimens in HL. Disclosures No relevant conflicts of interest to declare.


2002 ◽  
Vol 33 (10) ◽  
pp. 1044-1047 ◽  
Author(s):  
Riccardo Valdez ◽  
Paul McKeever ◽  
William G. Finn ◽  
Stephen Gebarski ◽  
Bertram Schnitzer

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Yasmin Sabet ◽  
Saul Ramirez ◽  
Elizabeth Rosell Cespedes ◽  
Marimer Rensoli Velasquez ◽  
Mateo Porres-Muñoz ◽  
...  

Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially fatal. We report the case of a twenty-nine-year-old female with Hodgkin’s lymphoma who was treated with brentuximab and later presented with severe acute pulmonary toxicity; she improved after the discontinuation of brentuximab and administration of antibiotics and glucocorticoid therapy. Currently there is very little data in the literature in regard to the clinical manifestations and characteristics of patients taking brentuximab and the potential development of acute severe pulmonary toxicity, as well as the appropriate therapeutic approach, making this particular case of successful treatment and resolution unique.


Sign in / Sign up

Export Citation Format

Share Document